Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(7))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section 45
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(8))
-URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Name:	us-gaap_PrepaidExpenseAndOtherAssetsCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

Significant agreements (Details) $ in Thousands	1 Months Ended	12 Months Ended
Significant agreements (Details) $ in Thousands	Jan. 31, 2020 item	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)
Significant agreements
Prepaid expenses and other current assets		$ 4,492	$ 2,734
Regeneron Pharmaceuticals, Inc
Significant agreements
Payments received under the terms of the agreement		5,100	3,000
Prepaid expenses and other current assets		$ 1,300	$ 971
Bristol-Myers Squibb Company
Significant agreements
Number Of Patients \| item	125